Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
To read the full story
Related Article
- MHLW Holds 1st Meeting to Consider Structure of Japan CDC
January 26, 2024
- MHLW Preparatory Council Boots Up for Japan-Version of CDC
October 13, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Japan Diet Enacts Bill to Create “Japan CDC”
June 1, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Lower House Clears Bill to Amend Next-Gen Medical Infrastructure Law
April 14, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- “Pseudonymized Medical Info” to Be Created to Fuel Healthcare Data Use in Filing
January 5, 2023
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
REGULATORY
- MHLW Plans Disposal of COVID-19 Antibody Meds in Government Stock
July 26, 2024
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
- Health Minister Hopes to Tap US Insights to Foster Japan Ecosystem
July 24, 2024
- MHLW Seeks Input to Gird for Summer Outbreaks, FPMAJ Ready to Ask for Ramp-Up
July 23, 2024
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…